There is huge potential in the successful execution of a platform which would significantly disrupt the existing market, lower barriers to innovation, and improve access to software services for users and new suppliers. This would benefit EU and global citizens by simplifying the access to digital innovation in operating rooms and improving patient outcomes and healthcare efficiency.
The Phase 2project is expected to lead to:
- Reduced development costs for SMEs and research groups. Conforming to hospital IS and IG requirements and integrating with the existing technical environment is simply too expensive, too time consuming and outside the core capabilities of many smaller clinical application innovators.
- Reduced costs to hospitals. Healthcare institutions are required to vet all new suppliers and then deal with installation and maintenance of multiple different software systems - a process that has considerable resource and cost implications. Fundamental to Cydar’s vision, is that once the PaaS is installed in hospitals, there will be no additional overhead every time a new clinical application is introduced.
- Increased access to healthcare technology at a decreased cost to the taxpayer. There is potential for significant savings across the EU once there is large scale deployment of the PaaS.